These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 24328486)

  • 41. Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?
    Jones AM; Barry PJ
    Thorax; 2015 Jul; 70(7):615-6. PubMed ID: 26071414
    [No Abstract]   [Full Text] [Related]  

  • 42. Aquagenic wrinkling of the palms in cystic fibrosis: comparison with controls and genotype-phenotype correlations.
    Berk DR; Ciliberto HM; Sweet SC; Ferkol TW; Bayliss SJ
    Arch Dermatol; 2009 Nov; 145(11):1296-9. PubMed ID: 19917960
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chronic ivacaftor treatment: getting F508del-CFTR into more trouble?
    Mall MA; Sheppard DN
    J Cyst Fibros; 2014 Dec; 13(6):605-7. PubMed ID: 25458465
    [No Abstract]   [Full Text] [Related]  

  • 44. Update in cystic fibrosis 2013.
    Jain M; Goss CH
    Am J Respir Crit Care Med; 2014 May; 189(10):1181-6. PubMed ID: 24832742
    [No Abstract]   [Full Text] [Related]  

  • 45. Carrier screening for cystic fibrosis in the new era of medications that restore CFTR function.
    Massie J; Castellani C; Grody WW
    Lancet; 2014 Mar; 383(9920):923-5. PubMed ID: 23992917
    [No Abstract]   [Full Text] [Related]  

  • 46. FDA OKs first in vitro route to expanded approval.
    Kingwell K
    Nat Rev Drug Discov; 2017 Sep; 16(9):591-592. PubMed ID: 28860581
    [No Abstract]   [Full Text] [Related]  

  • 47. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
    Yang H; Ma T
    Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Aquagenic wrinkling of the palms: a diagnostic clue to cystic fibrosis carrier status and non-classic disease.
    Thomas JM; Durack A; Sterling A; Todd PM; Tomson N
    Lancet; 2017 Feb; 389(10071):846. PubMed ID: 27665964
    [No Abstract]   [Full Text] [Related]  

  • 49. Aquagenic wrinkling and cystic fibrosis carriership: A dubious relationship.
    Castellani C; Boner AL
    Eur J Intern Med; 2018 Nov; 57():e43. PubMed ID: 30243510
    [No Abstract]   [Full Text] [Related]  

  • 50. Evaluating the predictive ability of sweat chloride.
    Heltshe SL; Rowe SM; Mayer-Hamblett N
    J Cyst Fibros; 2014 Jan; 13(1):118. PubMed ID: 23920003
    [No Abstract]   [Full Text] [Related]  

  • 51. Orphan cystic fibrosis drugs find sister diseases.
    Dolgin E
    Nat Med; 2011 Apr; 17(4):397. PubMed ID: 21475214
    [No Abstract]   [Full Text] [Related]  

  • 52. Aquagenic palmar wrinkling as a presenting feature of cystic fibrosis gene dysfunction.
    Stewart LC; Doe SJ; Bourke SJ; Leech S
    Clin Exp Dermatol; 2009 Dec; 34(8):e647-9. PubMed ID: 19548945
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Aquagenic wrinkling of the palms is due to vasoconstriction of palmar skin vasculature.
    Wilder-Smith EP
    Med Hypotheses; 2013 Nov; 81(5):963-5. PubMed ID: 24080203
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies.
    Antoniu SA
    Expert Opin Investig Drugs; 2011 Mar; 20(3):423-5. PubMed ID: 21303308
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ivacaftor improves appearance of sinus disease on computerised tomography in cystic fibrosis patients with G551D mutation.
    Sheikh SI; Long FR; McCoy KS; Johnson T; Ryan-Wenger NA; Hayes D
    Clin Otolaryngol; 2015 Feb; 40(1):16-21. PubMed ID: 25145599
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Aquagenic wrinkling of the palms in patients with cystic fibrosis homozygous for the delta F508 CFTR mutation.
    Katz KA; Yan AC; Turner ML
    Arch Dermatol; 2005 May; 141(5):621-4. PubMed ID: 15897385
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lung clearance index response in patients with CF with class III CFTR mutations.
    Kane M; Gonska T; Jensen R; Avolio J; Klingel M; Stanojevic S; Ratjen F
    Thorax; 2016 May; 71(5):476-7. PubMed ID: 26944510
    [No Abstract]   [Full Text] [Related]  

  • 58. Update in Cystic Fibrosis 2014.
    Ong T; Ramsey BW
    Am J Respir Crit Care Med; 2015 Sep; 192(6):669-75. PubMed ID: 26371812
    [No Abstract]   [Full Text] [Related]  

  • 59. Sweat Chloride Testing.
    McCarthy C; Clancy JP; Brewington J
    JAMA; 2019 Feb; 321(7):701-702. PubMed ID: 30698611
    [No Abstract]   [Full Text] [Related]  

  • 60. Lumacaftor/ivacaftor (Orkambi) for cystic fibrosis.
    Med Lett Drugs Ther; 2016 Mar; 58(1491):41-2. PubMed ID: 27027688
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.